脑转移全脑放疗中海马回避持续保护认知并预防患者报告症状:NRG Oncology CC001最终结果
NRG Oncology CC001三期试验最终结果显示,在518例脑转移患者中,全脑放疗联合美金刚基础上加用海马回避可预防认知功能失败(校正风险比0.74,P=0.016),并在6个月和12个月减少患者报告的症状负担、症状干扰和认知症状,总生存、颅内无进展生存和毒性无显著差异。
要点
- 海马回避全脑放疗联合美金刚可预防认知功能失败,校正风险比0.74,P=0.016。
- 海马回避组在6个月和12个月报告更少症状负担、症状干扰和认知症状。
- 两组总生存、颅内无进展生存和毒性无显著差异。
核心结论
- 中位随访超过1年,全脑放疗联合美金刚治疗脑转移时加用海马回避可持续保护认知功能,并持续预防患者报告的神经系统症状、症状干扰和认知症状,生存和毒性无差异。
研究设计与样本
- NRG Oncology CC001为三期随机对照试验,纳入成人脑转移患者,随机分配至海马回避全脑放疗联合美金刚组或全脑放疗联合美金刚组。
- 2015年7月至2018年3月共随机518例患者,存活患者中位随访12.1个月。
- 主要终点为认知功能失败时间,采用霍普金斯词语学习测验修订版(HVLT-R)、控制性口语词语联想测验或连线测验(TMT)A和B的可靠变化指数定义下降。
- 患者报告症状负担采用MD安德森症状量表脑肿瘤模块和EQ-5D-5L评估。
主要发现
- 全脑放疗联合美金刚基础上加用海马回避可预防认知功能失败,校正风险比0.74,P=0.016。
- 海马回避组4个月时TMT-B恶化更少(P=0.012),4个月时HVLT-R再认(P=0.055)和6个月时HVLT-R再认(P=0.011)恶化更少。
- 插补数据纵向模型显示海马回避组所有HVLT-R域保护更好(P<0.005)。
- 海马回避组6个月(插补数据P<0.001)和12个月(完整病例数据P=0.026;插补数据P<0.001)报告更少症状负担。
- 海马回避组6个月(完整病例数据P=0.003;插补数据P=0.0016)和12个月(完整病例数据P=0.0027;插补数据P=0.0014)报告更少症状干扰,随时间报告更少认知症状(插补数据P=0.043)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Initial report of NRG Oncology CC001, a phase 3 trial of whole-brain radiation therapy plus memantine (WBRT + memantine) with or without hippocampal avoidance (HA), demonstrated neuroprotective effects of HA with a median follow-up of fewer than 8 months. Herein, we report the final results with complete cognition, patient-reported outcomes, and longer-term follow-up exceeding 1 year. METHODS AND MATERIALS: Adult patients with brain metastases were randomized to HA-WBRT + memantine or WBRT + memantine. The primary endpoint was time to cognitive function failure, defined as decline using the reliable change index on the Hopkins Verbal Learning Test-Revised (HVLT-R), Controlled Oral Word Association, or the Trail Making Tests (TMT) A and B. Patient-reported symptom burden was assessed using the MD Anderson Symptom Inventory with Brain Tumor Module and EQ-5D-5L. RESULTS: Between July 2015 and March 2018, 518 patients were randomized. The median follow-up for living patients was 12.1 months. The addition of HA to WBRT + memantine prevented cognitive failure (adjusted hazard ratio, 0.74, P = .016) and was associated with less deterioration in TMT-B at 4 months (P = .012) and HVLT-R recognition at 4 (P = .055) and 6 months (P = .011). Longitudinal modeling of imputed data showed better preservation of all HVLT-R domains (P < .005). Patients who received HA-WBRT + Memantine reported less symptom burden at 6 (P < .001 using imputed data) and 12 months (P = .026 using complete-case data; P < .001 using imputed data), less symptom interference at 6 (P = .003 using complete-case data; P = .0016 using imputed data) and 12 months (P = .0027 using complete-case data; P = .0014 using imputed data), and fewer cognitive symptoms over time (P = .043 using imputed data). Treatment arms did not differ significantly in overall survival, intracranial progression-free survival, or toxicity. CONCLUSIONS: With median follow-up exceeding 1 year, HA during WBRT + memantine for brain metastases leads to sustained preservation of cognitive function and continued prevention of patient-reported neurologic symptoms, symptom interference, and cognitive symptoms with no difference in survival or toxicity.
引用
- Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023. PMID: 37150264. doi:10.1016/j.ijrobp.2023.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。